As expected, combining one anti-CSC therapy, such as anti-PD(L)1, with another, such as anti-HER2 or Nectin4, has an increased chance of providing an improved therapeutic ratio in drug vs. therapy development for cancer care. The gene discussed is ERBB2; the disease is cancer.